Free Trial
NYSE:TAK

Takeda Pharmaceutical (TAK) Stock Price, News & Analysis

Takeda Pharmaceutical logo
$15.07 +0.05 (+0.33%)
Closing price 03:59 PM Eastern
Extended Trading
$15.03 -0.04 (-0.27%)
As of 06:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Takeda Pharmaceutical Stock (NYSE:TAK)

Advanced

Key Stats

Today's Range
$15.03
$15.10
50-Day Range
$13.60
$15.50
52-Week Range
$12.80
$15.69
Volume
1.82 million shs
Average Volume
2.99 million shs
Market Capitalization
$47.95 billion
P/E Ratio
50.23
Dividend Yield
3.65%
Price Target
N/A
Consensus Rating
Hold

Company Overview

Takeda Pharmaceutical Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
56th Percentile Overall Score

TAK MarketRank™: 

Takeda Pharmaceutical scored higher than 56% of companies evaluated by MarketBeat, and ranked 553rd out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Earnings Growth

    Earnings for Takeda Pharmaceutical are expected to grow by 0.61% in the coming year, from $1.64 to $1.65 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Takeda Pharmaceutical is 50.23, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 279.98.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Takeda Pharmaceutical is 50.23, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 76.48.

  • Price to Book Value per Share Ratio

    Takeda Pharmaceutical has a P/B Ratio of 1.05. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Takeda Pharmaceutical's valuation and earnings.
  • Percentage of Shares Shorted

    0.25% of the float of Takeda Pharmaceutical has been sold short.
  • Short Interest Ratio / Days to Cover

    Takeda Pharmaceutical has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Takeda Pharmaceutical has recently decreased by 5.88%, indicating that investor sentiment is improving significantly.
  • Dividend Leadership

    Takeda Pharmaceutical is a leading dividend payer. It pays a dividend yield of 3.67%, putting its dividend yield in the top 25% of dividend-paying stocks.

  • Dividend Growth

    Takeda Pharmaceutical does not have a long track record of dividend growth.

  • Dividend Coverage

    The dividend payout ratio of Takeda Pharmaceutical is 183.33%. Payout ratios above 75% are not desirable because they may not be sustainable.

  • Dividend Sustainability

    Based on earnings estimates, Takeda Pharmaceutical will have a dividend payout ratio of 33.33% next year. This indicates that Takeda Pharmaceutical will be able to sustain or increase its dividend.

  • Read more about Takeda Pharmaceutical's dividend.
  • Percentage of Shares Shorted

    0.25% of the float of Takeda Pharmaceutical has been sold short.
  • Short Interest Ratio / Days to Cover

    Takeda Pharmaceutical has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Takeda Pharmaceutical has recently decreased by 5.88%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Takeda Pharmaceutical has a news sentiment score of 0.78. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 6 news articles for Takeda Pharmaceutical this week, compared to 5 articles on an average week.
  • Search Interest

    20 people have searched for TAK on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Takeda Pharmaceutical insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 0.04% of the stock of Takeda Pharmaceutical is held by insiders.

  • Percentage Held by Institutions

    Only 9.17% of the stock of Takeda Pharmaceutical is held by institutions.

  • Read more about Takeda Pharmaceutical's insider trading history.
Receive TAK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Takeda Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

TAK Stock News Headlines

Takeda Flat on Hookup with VELA
Arizona-made nanochips the new millionaire maker?
George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the last 40 years. Now he's stepping forward with an even bigger prediction about what's being built in the Arizona desert. He believes 3 little-known companies will explode when a bombshell announcement just days from now. Smart investors are already positioning themselves.tc pixel
See More Headlines

TAK Stock Analysis - Frequently Asked Questions

Takeda Pharmaceutical's stock was trading at $13.24 at the beginning of 2025. Since then, TAK stock has increased by 13.8% and is now trading at $15.07.

Takeda Pharmaceutical Co. (NYSE:TAK) posted its earnings results on Wednesday, July, 30th. The company reported $0.52 earnings per share for the quarter, topping the consensus estimate of $0.47 by $0.05. The business earned $7.45 billion during the quarter, compared to analysts' expectations of $7.96 billion. Takeda Pharmaceutical had a net margin of 3.20% and a trailing twelve-month return on equity of 10.50%.
Read the conference call transcript
.

Takeda Pharmaceutical subsidiaries include PvP Biologics, Shire, TiGenix, ARIAD Pharmaceuticals, Inviragen, LigoCyte Pharmaceuticals, Intellikine, and others.

Takeda Pharmaceutical's top institutional investors include Brandes Investment Partners LP (0.12%), First Trust Advisors LP (0.08%), Adage Capital Partners GP L.L.C. (0.08%) and Managed Asset Portfolios LLC (0.05%).
View institutional ownership trends
.

Shares of TAK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Takeda Pharmaceutical investors own include Johnson & Johnson (JNJ), Meta Platforms (META), Taiwan Semiconductor Manufacturing (TSM), JPMorgan Chase & Co. (JPM), Alibaba Group (BABA), NVIDIA (NVDA) and Pfizer (PFE).

Company Calendar

Last Earnings
7/30/2025
Today
9/19/2025
Next Earnings (Estimated)
10/30/2025
Fiscal Year End
3/31/2026

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NYSE:TAK
CIK
1395064
Employees
47,455
Year Founded
1781

Profitability

EPS (Trailing Twelve Months)
$0.30
Trailing P/E Ratio
50.22
Forward P/E Ratio
9.19
P/E Growth
N/A
Net Income
$712.33 million
Net Margins
3.20%
Pretax Margin
3.82%
Return on Equity
10.50%
Return on Assets
5.10%

Debt

Debt-to-Equity Ratio
0.60
Current Ratio
1.16
Quick Ratio
0.59

Sales & Book Value

Annual Sales
$4.48 trillion
Price / Sales
0.01
Cash Flow
$3.17 per share
Price / Cash Flow
4.75
Book Value
$14.39 per share
Price / Book
1.05

Miscellaneous

Outstanding Shares
3,181,943,000
Free Float
3,180,670,000
Market Cap
$47.94 billion
Optionable
Optionable
Beta
0.22

Social Links

7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

This page (NYSE:TAK) was last updated on 9/19/2025 by MarketBeat.com Staff
From Our Partners